evt_9cc28b53-cede-535f-aa1f-ddefb0c5f78ccand_6ce27a9f-a766-57cb-8594-b42fb1547a71
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
phase3_result
evd_01d28f85-fc8b-5088-ab85-3954de0c7441, evd_34264518-cb4e-5279-b3c6-b4a02d49e103, evd_63dece49-295e-5f83-a40e-1ffeed792bc0, evd_b2a0f794-98e4-5aad-93b3-33af6ccf2b04, evd_cc37a131-9b18-5fed-b93e-02391e833a32, evd_cc744a3e-09cf-5552-ba82-93f1b132cc30, evd_d3b5a55a-2ddb-5c8e-9898-215ae8f4744b, evd_d7a7689f-efab-5309-baa1-3e1d2988b78cfact_8a9b31d1-32c2-5cbd-830e-c1e75338796e, fact_98cd76a3-c930-58ca-b25e-976284d6edd6, fact_f2f7d108-3e98-57b8-a947-11b576094aaarel_081ef461-3605-5b58-9515-1f1de0f70d40, rel_0c33f6f1-f170-558f-bbb6-a9c4ed493eae, rel_1990447d-d3e8-59ff-a17d-3d5ddcae19f1, rel_bf47d8ad-cb88-5ecb-949d-d7e2f2d5672e